Final NICE guidance published on Entyvio (vedolizumab), the first gut-selective treatment for ulcerative colitis
The National Institute for Health and Care Excellence (NICE) has published final Technology Appraisal Guidance (TAG) for vedolizumab (Entyvio®), the first gut-selective treatment for ulcerative colitis (UC).1
NICE has recommended vedolizumab for use on the NHS for adults with moderately to severely active UC across its full licenced indication.1 NICE recognised that vedolizumab is an innovative, cost effective option, which represents a step change in treatment because of its novel mode of action, providing long-term remission from symptoms, with a safety profile similar to placebo.1
NICE has listened and responded positively to many stakeholders involved in the Health Technology Assessment of vedolizumab for UC, including people living with the condition, the patient association, Crohn’s and Colitis UK, and to healthcare professionals.
Following today’s publication of the NICE TAG, clinical commissioning groups have an obligation to ensure that vedolizumab is made available to appropriate patients within three months and no later than 03 September 2015.1. For more information please visit MNT Website